Board of Directors
Founder and Chairman of the Board
Mr. Stevens is a career entrepreneur, investor and operator with over 20 years of experience. Most recently he founded Applied BioSciences Corp. (OTCQB: APPB). He previously served as a Managing Director at JAT Capital, L.P. managing a $1 billion portfolio focused on TMT, and a Portfolio Manager at S.A.C. Capital Advisors, L.P. since 2012 running a $250mm TMT Portfolio. Scott also served as the Co-Founder and Head of Research at Strata Capital Management from 2006-2012 where he was responsible for the investment process, idea generation, internal screens and analyst management.
Before joining Strata, Scott worked at Ivory Capital Group LLC, a long/short equity fund, from 2004-2006, with a primary focus in managing the firm’s technology portfolio. He was responsible for idea generation, investment analysis, position-sizing, position-hedging and trade recommendations. Prior to that, he worked at Coatue Capital L.L.C from 2001-2004, a fundamental value based long/short equity fund where he helped to build the fund over a three-year period and assisted in the creation of many of the firm’s investing templates and practices. Prior to Coatue, Scott worked at Merrill Lynch & Co. 1998-2001 as an Analyst in the Mergers & Acquisitions Group where he completed over $20B of transactions in various sectors including aerospace/defense, media, healthcare and energy. He also worked in Merrill’s Global Communications Group where he served as an Analyst for the Taurus Fund, a private equity fund specializing in early to mid-stage telecommunications investments.
Scott graduated from the University of Michigan (BA Economics).
Raymond W. Urbanski M.D., Ph.D.
Chief Executive Officer and Director
Dr. Raymond W. Urbanski, M.D., Ph.D. has been the Chief Executive Officer of Applied Biosciences since May 1, 2019. He is a well-established industry leading expert with an impressive background in clinical, research, and pharmaceutical industry expertise across oncology, cardiology, endocrinology, and immunology. Over the course of his career spanning over 20 years, Dr. Urbanski has been responsible for developing and overseeing numerous clinical studies, including Phase 3b and Phase 4 studies, for sunitinib (Sutent), exemestane (Aromasin), irinotecan (Camptosar), epirubicin (Ellence), axitinib, IGF1R inhibitor, and tremilimumab.
Dr. Urbanski joined the Applied BioSciences team having most recently served as Chief Medical Officer and then CEO of GT Biopharma, Inc. (OTCQB: GTBP). Prior to GT Biopharma, Dr. Urbanski served as Chief Medical Officer at Mannkind (NASDAQ: MNKD), Mylan, Inc. (NASDAQ: MYL) and at Metabolex, Inc. While at GT Biopharma and MannKind, Dr. Urbanski was responsible for establishing the R&D organization and leading the overall drug development activities. Most notably in his career, Dr. Urbanski spent eight years with Pfizer (NYSE: PFE), where he held several positions, including Vice President and Chief Medical Officer of the Established Products Business Unit, Senior Medical Director of Oncology Clinical R&D, Senior Medical Director of Breast Cancer Products and Medical Director of Diversified Products. While serving at Pfizer, his leadership accomplishments included the successful development and approval of numerous new drugs and new indications across several therapeutic areas. Prior to serving at Pfizer, Dr. Urbanski served as Vice President and Chief Medical Officer at Suntory Pharmaceuticals, Inc.
Dr. Urbanski received his PhD in Pharmacology from the University of Medicine and Dentistry of New Jersey, Graduate School of Biomedical Sciences (GSBS) and his MD from the New Jersey Medical School. He was awarded the GSBS Fellowship Award and the Michael W Pozen scholarship during his graduate studies and medical education, respectively. Dr. Urbanski completed his residency and research training at Thomas Jefferson University Hospital in Philadelphia as part of the American Board of Internal Medicine’s Clinical Investigator Pathway. Following his training he joined a large internal medicine practice in Philadelphia while co-founding and serving as President of Clinical Studies Associates (CSA, Inc.), an organization involved in the conduct of clinical studies. During his time in practice and early on in his career in the pharmaceutical industry he held roles of Sub-Investigator, Principle Investigator, and Medical Director in a large number of clinical trials across multiple therapeutic areas. Many led to peer-reviewed publications as well as presentations at national and international conferences.
Chris Bridges has served as our President since February 10, 2017, and as a director since March 9, 2017. Mr. Bridges has served as the Chief Executive Officer of Vessix Inx, a virtual payment systems business which provides payment services designed for the aviation industry, since January 2013. From January 2009 until September 2013, Mr. Bridges served as a director of Banctek Solutions, which provides merchant bankcard processing services to all types of merchants. From January 2005 until January 2008, Mr. Bridges was Executive Vice President – Acquisitions at PRS Assets, of Denver, Colorado.
Michael Beaubaire M.D.
Dr. Beaubaire currently serves as the Principal of a life science and healthcare advisory group providing investing and portfolio management, business development execution, strategic consulting and capital raising services to established equity funds, consulting organizations and start-up companies. He most recently served as CEO and Director of Immunomodulation, an emerging biotechnology company focused on developing breakthrough therapies to modulate immune responses in multiple high value oncology and serious infectious disease indications. Prior to that, he served as the Chair of the Scientific Advisory Board and Investment Team of Lincoln Park Capital LLC, a fundamental equity investor in life sciences, where he is responsible for assessing clinical and scientific opportunities in micro-cap and private life science organizations, as well as evaluating reviewing and overseeing investment opportunities. Other roles include advising emerging life science and device companies, healthcare service organizations, and interested institutional healthcare investors through his own advisory firm and affiliating with leading investment banks and strategic management consulting firms.
Dr. Beaubaire earned his BS with Honors in Finance from the Wharton School, and his BA with Honors in Biological Basis of Behavior from the College of Arts & Sciences, both at the University of Pennsylvania. He received his Medical Doctorate degree from Northwestern University Medical School, and trained as an Internal Medicine resident at Evanston Northwestern Healthcare where he served as an educator to medical interns and students under his tutelage.